



# *Divi's Laboratories Limited*

Date. 5<sup>th</sup> February 2016

The Secretary  
**BSE Limited**  
1<sup>st</sup> Floor, New Trading Ring, Rotunda Bldg.,  
P.J. Towers, Dalal Street, Fort  
MUMBAI – 400 023

Dear Sir,

**Sub: Un-audited financial results for the quarter and nine months ended  
31<sup>st</sup> December 2015 and limited review report –reg**  
**Ref: Stock code: 532488**


Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed un-audited financial results along with the limited review report for the quarter and nine months ended 31<sup>st</sup> December 2015.

Above un-audited financials were approved and taken on record by the Board of Directors of the Company at their meeting held on Friday, 5<sup>th</sup> February 2016.

The Company proposes release of press note as per the enclosed format. This is for your information and records. Kindly acknowledge the receipt of the same.

Thanking You,

Yours faithfully,  
**For Divi's Laboratories Limited**

  
P V Lakshmi Rajani  
Company Secretary  
(ACS 18882)



CIN : L24110TG1990PLC011854

**“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”**

**Regd. Off :** Divi Towers, 7-1-77/E/1/303, Dharam Karan Road, Ameerpet, Hyderabad - 500 016. INDIA  
Tel : 91-40-2378 6300, Fax : 91-40-2378 6460  
E-mail : mail@divislaboratories.com, Website : www.divislaboratories.com

**DIVI'S LABORATORIES LIMITED**

UN-AUDITED FINANCIAL RESULTS (STANDALONE)  
FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>st</sup> DECEMBER, 2015

(Rs.in Lakhs)

	Particulars	STANDALONE					
		Quarter ended			Nine Months ended		Year Ended
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	<b>Income from operations</b>	<b>85177</b>	96187	78808	<b>262055</b>	225761	307230
	(a) Net Sales/Income from operations (Net of Excise Duty)						
	(b) Other Operating Income	<b>110</b>	245	304	<b>540</b>	931	1171
	<b>Total Income from operations (net)</b>	<b>85287</b>	96432	79112	<b>262595</b>	226692	308401
2	<b>Expenses</b>						
	a. Cost of materials consumed	<b>33258</b>	42106	34672	<b>110931</b>	105441	144627
	b. Purchases of stock-in-trade	<b>0</b>			<b>0</b>		0
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	<b>(1512)</b>	(3571)	(2808)	<b>(8596)</b>	(13626)	(23083)
	d. Employee benefits expense	<b>9118</b>	8595	7459	<b>25746</b>	20425	28315
	e. Depreciation and amortization expense	<b>2988</b>	3007	2879	<b>8887</b>	9131	13585
	f. Other Expenses	<b>12194</b>	11702	11080	<b>34700</b>	31546	42337
	<b>Total Expenses</b>	<b>56046</b>	61839	53282	<b>171668</b>	152917	205781
3	<b>Profit from Operations before Other Income, Finance Costs &amp; Exceptional Items (1-2)</b>	<b>29241</b>	34593	25830	<b>90927</b>	73775	102620
4	Other Income	<b>1520</b>	2964	1994	<b>7883</b>	4817	4284
5	<b>Profit from ordinary activities before finance costs &amp; exceptional items (3+4)</b>	<b>30761</b>	37557	27824	<b>98810</b>	78592	106904
6	Finance Costs	<b>23</b>	34	48	<b>79</b>	127	186
7	<b>Profit from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>30738</b>	37523	27776	<b>98731</b>	78465	106718
8	Exceptional items	<b>0</b>	0	0	<b>0</b>	0	0
9	<b>Profit from ordinary activities before Tax (7-8)</b>	<b>30738</b>	37523	27776	<b>98731</b>	78465	106718
10	Tax Expense	<b>6082</b>	7950	5718	<b>20184</b>	16650	22012
11	<b>Net Profit from ordinary activities after Tax (9-10)</b>	<b>24656</b>	29573	22058	<b>78547</b>	61815	84706
12	Extra-ordinary items (net of tax expense)	<b>0</b>	0	0	<b>0</b>	0	0
13	<b>Net Profit (+)/Loss(-) for the period (11-12)</b>	<b>24656</b>	29573	22058	<b>78547</b>	61815	84706
14	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	<b>5309</b>	5309	2655	<b>5309</b>	2655	2655



15	Reserves excluding revaluation reserves as per balance sheet of previous accounting year							353541
16	<b>Earnings per Share (of Rs.2/- each) (not annualized):</b>							
	a) Basic	9.29	11.14	8.31	29.59	23.29		31.91
	b) Diluted	9.29	11.14	8.31	29.59	23.29		31.91

**NOTES:**

1. The above results for the quarter ended 31<sup>st</sup> December 2015, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 5<sup>th</sup> February, 2016 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. The company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
4. Details of forex gain/loss are given below:

Particulars	Quarter ended			Nine Months ended		Year Ended
	31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Forex Gain/(Loss)	294	1166	1116	3582	1683	(105)

Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

5. Bonus Issue: The company has allotted 13,27,34,290 bonus shares of Rs.2 each to the members on 28<sup>th</sup> September, 2015. Earnings per Share has been adjusted for previous periods presented due to the bonus issue, in accordance with Accounting Standard No.20.
6. Upon enactment of the Payment of Bonus (Amendment) Act, 2015, the company has made additional provision for bonus to employees, during the quarter, amounting to Rs.257 lakhs for the previous year 2014-15.
7. Figures for the previous year/period have been regrouped or reclassified, wherever necessary.

Place: Visakhapatnam  
Date: 05-02-2016



for Divi's Laboratories Limited

Dr. Murali K. Divi  
Chairman & Managing Director



## INDEPENDENT AUDITOR'S REVIEW REPORT


TO  
THE BOARD OF DIRECTORS OF  
DIVI'S LABORATORIES LIMITED

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **DIVI'S LABORATORIES LIMITED** ("the company") for the quarter and nine months ended **31<sup>st</sup> December, 2015** ("the Statement"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Accounting Standards and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.V.R.K. NAGESWARA RAO & Co.,  
Chartered Accountants  
Firm's Registration Number: 002283S

  
N. ANKA RAO  
Partner  
Membership Number: 23939



VISAKHAPATNAM  
05.02.2016

**DIVI'S LABORATORIES LIMITED**  
Hyderabad

**PRESS RELEASE dated 5<sup>th</sup> February, 2016**

**Divi's Labs earns a PAT of Rs.247 crores in Q3/FY16**

Divi's Laboratories has earned a Profit after Tax (PAT) of Rs.247 crores on a total income of Rs.853 crores, on a stand-alone basis, for the quarter ended 31<sup>st</sup> December, 2015. For the corresponding quarter of the last year the company earned a PAT of Rs.221 crores on a total income of Rs. 791 crores.

Forex gain for the current quarter amounted to Rs.3 crores as against a forex gain of Rs.11 crores during the corresponding quarter last year. The company has capitalized fixed assets aggregating to Rs.34 crores during the current quarter.

For the 9-month period ended 31<sup>st</sup> December, 2015, the company earned a total income of Rs.2626 crores as compared to Rs. 2267 crores during the corresponding 9-month period of last year. PBT for the current 9-month period came to Rs.987 crores as against a PBT of Rs. 785 crores for the previous period. PAT for the current 9-months is Rs.785 crores as against Rs. 618 crores for the previous period.

